Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaPP3 aspirin dose non-inferiority trial in Lynch syndrome
2014-000411-14Phase 3Unknown
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspirin in hereditary nonpolyposis colorectal cancer (HNPCC) (3 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Number of new primary mismatch repair deficient cancers. Status: unknown.
02
Drugs
aspirin
03
Conditions
hereditary nonpolyposis colorectal cancer (HNPCC)
Beyond the preview
Go deeper on 2014-000411-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000411-14.